Fresenius Kabi STIMUFEND (pegfilgrastim-fpgk) Coding and Reimbursement Guide

STIMUFEND®(pegfilgrastim-fpgk)is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.


Fresenius Kabi STIMUFEND (pegfilgrastim-fpgk) Coding and Reimbursement Guide - cover page
Brand
Fresenius Kabi
Category
Drugs
Document type
Other
Language
English
Pages
20
File format
PDF
File size
1.1 MB
Published
16 November, 2023
Updated
16 November, 2023
MD5 checksum
1004F290F0BC35EE14E5A52EE70F2D7D

About this manual

This 20-page guide from Fresenius Kabi covers coding, coverage, billing and reimbursement for STIMUFEND (pegfilgrastim-fpgk), a pegfilgrastim biosimilar. It lists the indication and limitations of use, the recommended dosage and administration, and the codes used on claims: HCPCS Q5127, CPT 96372, ICD-10-CM diagnosis codes, 10- and 11-digit NDC numbers and hospital revenue codes.

The guide also describes the treatment approval and reimbursement process, including benefits verification, prior authorization, copay support through KabiCare, submitting the claim form, payment rates for injectable drugs, submitting for copay assistance, and claim denials and appeals. Important Safety Information is repeated throughout the brochure. The information is stated to be current as of September 2022.

What's inside

  • About the STIMUFEND Coding and Reimbursement Guide
  • STIMUFEND coding overview
  • STIMUFEND treatment approval process
  • Benefits verification
  • Prior authorization (PA)
  • Copay support
  • STIMUFEND reimbursement process
  • Submitting the claim form
  • Reimbursement for injectable drugs—payment rates
  • Submitting for copay assistance

Specifications

Recommended dosage (adults)Single subcutaneous injection of 6 mg once per chemotherapy cycle
AdministrationSubcutaneous injection via a single-dose, pre-filled syringe for manual use
Package and 10-digit NDC6-mg/0.6-mL single-dose, pre-filled syringe; 65219-371-10
11-digit NDC65219037110
HCPCS codeQ5127 — Injection, pegfilgrastim-fpgk, biosimilar, (STIMUFEND), 0.5 mg
Billable units12 billable units for administration of 1 syringe
CPT code for injection96372 — Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular
Discarded product reportingReported on a separate line with Q5127 and the JW modifier

Frequently asked questions

What is STIMUFEND indicated for?

It is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.

How is STIMUFEND administered?

It is administered subcutaneously via a single-dose, pre-filled syringe for manual use.

What is the recommended dosage for adult patients?

For adult patients with non-myeloid cancer receiving myelosuppressive chemotherapy, the recommended dosage is a single subcutaneous injection of 6 mg once per chemotherapy cycle.

Which HCPCS code is assigned to STIMUFEND?

The HCPCS Q-code assigned to STIMUFEND is Q5127, Injection, pegfilgrastim-fpgk, biosimilar, (STIMUFEND), 0.5 mg, effective for dates of service on and after April 1, 2023.

Download PDF (1.1 MB)

More Fresenius Kabi Manuals


View all Fresenius Kabi manuals →